Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Skyrizi (risankizumab-rzaa) and Humira (adalimumab) are prescription drugs that treat conditions such as psoriatic arthritis. The cost of both drugs depends on several factors. Skyrizi and Humira are ...

Skyrizi may lead to mild side effects, including headaches, fatigue, injection site reactions, and upper respiratory infections. Serious side effects, such as an increased risk of infections, may ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

AbbVie has big plans to grow sales for Humira follow-ups Skyrizi and upadacitinib. Early into its Skyrizi launch for psoriasis, the company has offered discounts on its megablockbuster Humira to ...

AbbVie ABBV announced the submission of regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its drug Skyrizi (risankizumab) for a new indication, moderately to ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely ...

AbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s ...

In studies, the injected medicine helped a significant number of people with UC find relief from moderate to severe symptoms. The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as ...